However, recent clinical trials on ovarian cancer with a selective progesterone receptor modulator, such as mifepristone, have largely been unsuccessful, despite high in vitro antagonist activity in nuclear PR (Rocereto et al., 2010; Ponikwicka-Tyszko et al., 2019). This evidence concerns the gene PGR and ovarian cancer.